XAIR ▲ +26.1% - Beyond Air, Inc. $XAIR - Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Beyond Air's stock surged 26.1% following the company's announcement that the FDA has granted Breakthrough Device Designation for its LungFit® GO system to treat nontuberculous mycobacterial pulmonary disease. This designation accelerates the development and review pathway for the device, signaling FDA recognition of its potential as a meaningful treatment option for a serious condition with limited therapeutic alternatives. 31-AUG-2026 08:01 AM ET